ALFAMINO® HMO:
ADVANCING THE MANAGEMENT OF SEVERE COW’S MILK PROTEIN ALLERGY
- Amino acid-based, hypoallergenic formula (AAF) for effective first-line relief from severe symptoms of cow’s milk protein allergy (CMPA) and/or multiple food allergies and/or malabsorptive conditions*1-6
- Contains 2’FL and LNnT†, to nurture infants’ developing immune systems7-11
- Designed to support gastrointestinal tolerance and to facilitate absorption in the most challenging conditions12-19
- Supports normal growth and development20,21
- Preferred taste over other AAF, which may increase long-term acceptance22
- Nutritionally complete. Suitable as a sole source of nutrition from birth or supplementary feeding from 6 months of age
Effectively relieves symptoms, supports gut recovery and healthy growth
Infants with CMPA and/or multiple food allergies may face an immediate challenge from skin, gastrointestinal and/or respiratory symptoms, while those with severe symptoms may also experience anaphylaxis, failure to thrive and/or complex gastrointestinal manifestations.4-6,23 Alfamino® HMO is proven to be hypoallergenic, provides effective symptom relief1-3 and supports normal growth.20,21
Skin symptoms
(e.g. eczema, urticaria…)
Gastrointestinal symptoms
(e.g. vomiting, colic, diarrhoea…)
Respiratory symptoms
(e.g. wheezing…)
General symptoms
(e.g. inconsolable crying, failure to thrive, anaphylaxis…)
Alfamino® HMO’s is also designed to facilitate fat and calcium absorption and supports gut recovery.12-19 This is due to it’s unique composition which is lactose-free and low in osmolality. It also contains 24% medium-chain triglycerides (of total fat) and structured lipids.
Immune-nurturing benefits
CMPA is an immune-mediated disease. It is associated with gut microbiota dysbiosis, which impacts immune system maturation and leaves infants at an increased risk of infections and future allergies.25-33 Alfamino® HMO is the only amino acid-based formula to contain 2’-fucosyllactose (2’FL) and lacto-N-neotetraose (LNnT), which are structurally identical to two significant human milk oligosaccharides (HMO).+7-11
HMO support the growth of beneficial bacteria in the gut
HMO strengthen the gut barrier by promoting intestinal cell maturation
HMO eliminate pathogens through a decoy effect
HMO guide the maturation of the immune system, leading to a more balanced Th1/Th2 response
REDUCING INFECTIONS AND MEDICATION USE
Infants fed formula with 2’FL and LNnT† had fewer upper and lower respiratory tract infections6-8
Infants fed formula with 2’FL and LNnT† had lower antibiotic and antipyretic use6-8
MEET SOPHIA
Feeding:
Formula-fed and complementary feeding
Symptoms:
Unsettled, persistent crying, vomiting & severe diarrhoea and faltering growth
Diagnosis:
Suspected multiple food allergies including CMPA
Fictional patient profile for illustrative purpose only
WHAT WOULD BE YOUR MOST IMPORTANT GOAL FOR SOPHIA?
- SYMPTOM RELIEF
- SUPPORT GROWTH
- SUPPORT IMMUNE HEALTH
For infants with multiple food allergies, including CMPA, who are complementary feeding but cannot be breastfed, symptom relief can be achieved by:
- A complementary diet with the elimination of the foods suspected of causing an allergic reaction4,5
- A proven amino acid-based formula, such as Alfamino® HMO, which has been shown to be safe and effective for infants with CMPA:1-3
CMPA and food allergies in general may impair growth as some symptoms may affect nutritional intake and/or the absorption of nutrients.4,5 Alfamino® HMO is nutritionally tailored for infants with severe symptoms of CMPA and other food allergies, and has been proven to support healthy growth and development:20,21
The development of the immune system of infants with CMPA is affected by gut microbiota dysbiosis and increased gut permeability.24-26,34
Alfamino® HMO is the only amino acid-based formula with 2’FL and LNnT to support the development of the immune system and reduce the risk of infections and associated medication use:9-11
HEALTHY INFANTS8 Mean trial duration: 12 months |
INFANTS WITH CMPA6,7 Mean trial duration: 8.8 months |
|
---|---|---|
EAR INFECTIONS | -46%‡ | -71%‡ |
LOWER RESPIRATORY TRACT INFECTIONS | -55%* | -34%‡ |
BRONCHITIS | -70%** | |
GASTROINTESTINAL INFECTIONS | -40%‡ | |
FREQUENCY OF UPPER RESPIRATORY TRACT INFECTIONS | -42%* | |
ANTIBIOTIC USE | -53%* | -6%‡ |
ANTIPYRETIC USE | -56%*** | -11%‡ |
*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.05 at 4 months only; ‡ p = N.S.